Camino Pharma
It is focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $2.0m | Grant |
| Total Funding | 000k | ||
Related Content
Camino Pharma, LLC is a preclinical-stage biotechnology firm established in 2018, concentrating on the development of new treatments for central nervous system (CNS) disorders. The company's scientific foundation is built upon the research of its co-founders, Dr. P. Jeffrey Conn and Dr. Craig W. Lindsley, who are recognized for their work in G-protein coupled receptor (GPCR) drug discovery at Vanderbilt University. Dr. Conn serves as the Director of the Vanderbilt Center for Neuroscience Drug Discovery, and Dr. Lindsley is the Director of the Warren Center for Neuroscience Drug Discovery (WCNDD), bringing extensive experience in neuroscience and medicinal chemistry to the venture.
The company's primary focus is on advancing allosteric modulators that target muscarinic acetylcholine receptors, specifically the M1 and M4 subtypes. This approach aims to provide more precise treatments for conditions like schizophrenia, psychosis in Alzheimer's disease, and other neurological and psychiatric disorders. Camino Pharma's lead programs are designed to offer improved safety and efficacy compared to existing therapies by selectively modulating these receptors. The business operates within the biopharmaceutical sector, a market characterized by long development cycles and high regulatory hurdles.
Camino Pharma's business model is centered on advancing its drug candidates through preclinical development to a stage where they can be partnered or licensed to larger pharmaceutical companies for further clinical trials and commercialization. In a significant milestone, the company entered into an exclusive worldwide license and collaboration agreement with Karuna Therapeutics (a wholly-owned subsidiary of Bristol Myers Squibb) in 2024. Under this agreement, Camino Pharma granted Karuna exclusive rights to its TRPC4/5 channel antagonists, a novel, non-opioid mechanism for treating pain. This collaboration provided Camino Pharma with an upfront payment and the potential for future milestone payments and royalties, validating its discovery platform and providing capital to advance its core CNS pipeline.
Keywords: biotechnology, central nervous system, CNS disorders, drug discovery, allosteric modulators, muscarinic receptors, preclinical, neuroscience, biopharmaceutical, licensing agreement